drugset / Trial / NCT02982720
Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron
Phase 2
Terminated
4 enrolled
Aiwu Ruth He, MD
Georgetown University · collabHoosier Cancer Research Network · collabMerck Sharp & Dohme LLC · collabRoswell Park Cancer Institute · collabThe Cleveland Clinic · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, single-arm, multicenter Phase II safety and efficacy study of combination therapy with pembrolizumab and Sylatron (Peginterferon alpha-2b) in patients with advanced cholangiocarcinoma who have progressed on or cannot tolerate frontline chemotherapy.
Timeline
- Start
- 2017-07-05
- Primary completion
- 2018-02-09
- Completion
- 2018-02-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | 200 ug | Subcutaneous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |